Johnson & Johnson (J&J) is an American multinational corporation and the world's largest healthcare organization, focusing on Innovative Medicine and MedTech. Founded in 1886, it is headquartered in New Brunswick, New Jersey, and is one of only two U.S. companies with a AAA credit rating. 

Core Business Segments

In 2023, J&J spun off its consumer health division (brands like Tylenol and Band-Aid) into a separate company called Kenvue. It now operates in two primary areas: 

• Innovative Medicine (formerly Janssen): Develops breakthrough treatments in oncology, immunology, neuroscience, and cardiovascular diseases.
• MedTech: Focuses on interventional solutions, orthopaedics, surgery, and vision. 

2026 Financial & Operational Status 

As of January 2026, Johnson & Johnson continues to be a major market leader: 

• Market Standing: Its stock (JNJ) is a component of the Dow Jones Industrial Average with a market capitalization exceeding $526 billion as of early 2026.
• Upcoming Earnings: The company is scheduled to report its Q4 2025 earnings on January 21, 2026.
• Recent Innovations: In January 2026, the company launched the Arbrea Breast Simulator Surgeon App for 3D patient visualizations and announced positive Phase 3 results for MajesTEC-9 in treating multiple myeloma.
• Future Investments: J&J has pledged to invest $55 billion in the U.S. by 2029, including new manufacturing facilities in North Carolina and Pennsylvania. 

Key Products & Legacy

• Innovative Medicine: Key therapies include TECVAYLI® (multiple myeloma), Spravato® (antidepressant), and CAPLYTA® (major depressive disorder).
• Vision Care: Home to ACUVUE®, the world's most trusted contact lens brand.
• Historical Firsts: Credited with creating the first commercial first aid kit (1888), sterile surgical dressings (1886), and the BAND-AID® (1921). 

Leadership & Careers

• Leadership: Led by Chairman and CEO Joaquin Duato.
• Career Opportunities: Interested candidates can apply for global roles and internships via the Johnson & Johnson Careers portal.